BioCentury | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Microtubule-associated protein τ (tau; MAPT; FTDP-17); Rho-associated coiled-coil containing protein kinase 1 (ROCK1); ROCK2

Neurology INDICATION: Progressive supranuclear palsy (PSP) Patient sample and fruit fly studies suggest ROCK1 or ROCK2 inhibitors could help treat PSP and corticobasal degeneration (CBD), which is caused by neuronal accumulation of a four-repeat isoform...
BioCentury | Aug 18, 2014
Company News

Gentris, Cancer Genetics deal

...Cancer Genetics acquired Gentris, which provides next-generation sequencing and biomarker services, for $3.3 million in cash...
...next-generation sequencing and biomarker services, for $3.3 million in cash plus $1.5 million in stock. Gentris...
...services for genomic and biomarker testing. Gentris has operations in Raleigh, N.C., and Shanghai, China. Gentris Corp....
BioCentury | Jun 30, 2014
Company News

Gentris, Cancer Genetics deal

...Cancer Genetics signed a non-binding letter of intent to acquire Gentris for about $4.8 million, comprising...
...serve as general manager during the integration of Gentris’ Raleigh facility and Howard McLeod, a Gentris...
...said Gentris’ expertise in pharmacogenomics will be “highly complementary” to Cancer Genetics’ oncology diagnostic business. Gentris Corp....
BioCentury | Jul 2, 2012
Company News

Gentris, Shanghai Institutes of Preventative Medicine deal

...the deal will focus on therapeutic areas that include oncology, infectious disease and chronic disease. Gentris...
...identifying U.S. sponsors for the projects, and the institute will seek support from Chinese organizations. Gentris...
...training and education programs focused on pharmacogenomics and clinical sample banking. Details were not disclosed. Gentris Corp....
BioCentury | Jun 28, 2010
Company News

Gentris management update

Gentris Corp. , Research Triangle Park, N.C. Business: Pharmacogenetics Hired: Rick Williams as CEO and a director, formerly CBO at The Hamner Institutes WIR Staff...
BioCentury | Sep 3, 2007
Company News

Gentris, ParagonDx deal

...ParagonDx acquired the assets of Gentris' Gentris Diagnostics Inc. subsidiary for an undisclosed sum. The acquisition...
...and former CEO of Stratagene Corp. (STGN, La Jolla, Calif.), owns 67% of ParagonDx, while Gentris...
...Gentris Clinical Genetics Inc. subsidiary, which provides pharmacogenetic testing services to biotech and pharmaceutical companies. Gentris Corp....
BioCentury | Mar 21, 2005
Company News

Gentris management update

Gentris Corp. , Morrisville, N.C. Business: Pharmacogenetics Hired: Deborah Oronzio as VP of business development and marketing, formerly manager of business development at Metrigenix Inc.; and Sandra Sonnessa as VP of corporate development, formerly practice manager...
BioCentury | Aug 2, 2004
Company News

AutoGenomics, Gentris deal

...The companies will integrate Gentris' CYP450 diagnostic products with AutoGenomics' Infiniti automated multiplexing microarray platform to...
...molecular diagnostics that detect genetic mutations associated with drug metabolism. AutoGenomics Inc. , Carlsbad, Calif. Gentris Corp....
BioCentury | Jun 28, 2004
Company News

Gentris, Tranzyme deal

...cell lines for use as genetic controls for diagnostic assays that measure patients' drug responses. Gentris...
...create recombinant cell lines expressing the sequences. The companies will jointly own resulting cell lines. Gentris Corp....
BioCentury | Mar 3, 2003
Company News

Gentris, Sankyo deal

...Under a non-exclusive three-year deal, Gentris and Sankyo's Sankyo Pharma Inc. subsidiary will develop a pharmacogenomic...
...and Sankyo's Sankyo Pharma Inc. subsidiary will develop a pharmacogenomic test panel based on existing Gentris...
...development programs. The companies also plan to develop diagnostics for use with Sankyo Pharma's compounds. Gentris Corp....
Items per page:
1 - 10 of 17
BioCentury | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Microtubule-associated protein τ (tau; MAPT; FTDP-17); Rho-associated coiled-coil containing protein kinase 1 (ROCK1); ROCK2

Neurology INDICATION: Progressive supranuclear palsy (PSP) Patient sample and fruit fly studies suggest ROCK1 or ROCK2 inhibitors could help treat PSP and corticobasal degeneration (CBD), which is caused by neuronal accumulation of a four-repeat isoform...
BioCentury | Aug 18, 2014
Company News

Gentris, Cancer Genetics deal

...Cancer Genetics acquired Gentris, which provides next-generation sequencing and biomarker services, for $3.3 million in cash...
...next-generation sequencing and biomarker services, for $3.3 million in cash plus $1.5 million in stock. Gentris...
...services for genomic and biomarker testing. Gentris has operations in Raleigh, N.C., and Shanghai, China. Gentris Corp....
BioCentury | Jun 30, 2014
Company News

Gentris, Cancer Genetics deal

...Cancer Genetics signed a non-binding letter of intent to acquire Gentris for about $4.8 million, comprising...
...serve as general manager during the integration of Gentris’ Raleigh facility and Howard McLeod, a Gentris...
...said Gentris’ expertise in pharmacogenomics will be “highly complementary” to Cancer Genetics’ oncology diagnostic business. Gentris Corp....
BioCentury | Jul 2, 2012
Company News

Gentris, Shanghai Institutes of Preventative Medicine deal

...the deal will focus on therapeutic areas that include oncology, infectious disease and chronic disease. Gentris...
...identifying U.S. sponsors for the projects, and the institute will seek support from Chinese organizations. Gentris...
...training and education programs focused on pharmacogenomics and clinical sample banking. Details were not disclosed. Gentris Corp....
BioCentury | Jun 28, 2010
Company News

Gentris management update

Gentris Corp. , Research Triangle Park, N.C. Business: Pharmacogenetics Hired: Rick Williams as CEO and a director, formerly CBO at The Hamner Institutes WIR Staff...
BioCentury | Sep 3, 2007
Company News

Gentris, ParagonDx deal

...ParagonDx acquired the assets of Gentris' Gentris Diagnostics Inc. subsidiary for an undisclosed sum. The acquisition...
...and former CEO of Stratagene Corp. (STGN, La Jolla, Calif.), owns 67% of ParagonDx, while Gentris...
...Gentris Clinical Genetics Inc. subsidiary, which provides pharmacogenetic testing services to biotech and pharmaceutical companies. Gentris Corp....
BioCentury | Mar 21, 2005
Company News

Gentris management update

Gentris Corp. , Morrisville, N.C. Business: Pharmacogenetics Hired: Deborah Oronzio as VP of business development and marketing, formerly manager of business development at Metrigenix Inc.; and Sandra Sonnessa as VP of corporate development, formerly practice manager...
BioCentury | Aug 2, 2004
Company News

AutoGenomics, Gentris deal

...The companies will integrate Gentris' CYP450 diagnostic products with AutoGenomics' Infiniti automated multiplexing microarray platform to...
...molecular diagnostics that detect genetic mutations associated with drug metabolism. AutoGenomics Inc. , Carlsbad, Calif. Gentris Corp....
BioCentury | Jun 28, 2004
Company News

Gentris, Tranzyme deal

...cell lines for use as genetic controls for diagnostic assays that measure patients' drug responses. Gentris...
...create recombinant cell lines expressing the sequences. The companies will jointly own resulting cell lines. Gentris Corp....
BioCentury | Mar 3, 2003
Company News

Gentris, Sankyo deal

...Under a non-exclusive three-year deal, Gentris and Sankyo's Sankyo Pharma Inc. subsidiary will develop a pharmacogenomic...
...and Sankyo's Sankyo Pharma Inc. subsidiary will develop a pharmacogenomic test panel based on existing Gentris...
...development programs. The companies also plan to develop diagnostics for use with Sankyo Pharma's compounds. Gentris Corp....
Items per page:
1 - 10 of 17